Insights Center

Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.

Featured

Mintz Direct

On our new Mintz Direct page, Mintz thought leaders across industries and practice areas offer timely insights on developments that impact our clients and communities. Visit the Mintz Direct page to hear what our experienced attorneys and professionals are saying about what’s happening now.

Mintz Viewpoints

Use quotation marks to search for an exact phrase (e.g. “class action”)

Published

Showing 6609 - 6616 of 12007 results

CMS Completes Final Medicare Part D Reconciliation for 2016

October 11, 2017| Blog| Viewpoint

What To Know About Boston's Status As A 'Sanctuary City'

October 11, 2017| News

U.S. Visa Processing in Turkey Suspended Amid Security Concerns; Turkey Responds in Kind

October 10, 2017| Alert| Viewpoint

OTC Drug Manufacturers: Keep Your Eyes and Ears on Congress

October 10, 2017| Blog| Viewpoint

Building a Health App? Part 4: Avoiding an FTC Enforcement Action

October 10, 2017| Blog| Viewpoint

Department of Veterans Affairs Aims to Trump State Telemedicine Rules

October 10, 2017| Blog| Viewpoint

Health Care Weekly Preview from ML Strategies – Week of October 9, 2017

October 10, 2017| Blog| Viewpoint

InsureTech Connect 2017 Panel Discussion: Maximizing Profits via Products and Alternative Business Model Innovation

October 9, 2017| Article| Viewpoint

News & Press Releases

Mintz Advises ArriVent BioPharma on $75 Million Underwritten Public Offering

July 08, 2025

Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“

Mintz Advises S2G Investments on $40M Series B Financing of Sojo Industries

July 07, 2025

Mintz represented S2G Investments, a multi-stage investment firm focused on venture and growth-stage businesses across food & agriculture, oceans and energy, in its $40 million Series B financing of Sojo Industries, an industrial automation company that utilizes robotics, mobility, and software to deliver packaging and assembly solutions to the food and beverage industry.

Mintz Advises Syntis Bio on $33 Million Series A Financing

July 02, 2025

Mintz advised Syntis Bio, a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes, and rare diseases, on a $33 million oversubscribed Series A financing.

View all News and Press Releases